Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Valbenazine for the treatment of tardive dyskinesia.

Seeberger LC, Hauser RA.

Expert Opin Pharmacother. 2017 Aug;18(12):1279-1287. doi: 10.1080/14656566.2017.1353078. Epub 2017 Aug 2.

PMID:
28699794
2.

Carbidopa levodopa enteral suspension.

Seeberger LC, Hauser RA.

Expert Opin Pharmacother. 2015;16(18):2807-17. doi: 10.1517/14656566.2015.1111336. Epub 2015 Nov 23. Review. Erratum in: Expert Opin Pharmacother. 2016;17(5):751.

PMID:
26595228
3.

Rasagiline: time to onset of antiparkinson effect is similar when used as a monotherapy or adjunct treatment.

Wilson RE, Seeberger LC, Silver D, Griffith A, Conner JB, Salzman PM; LEGATO Investigators.

Neurologist. 2011 Nov;17(6):318-24. doi: 10.1097/NRL.0b013e31822f6872.

PMID:
22045282
4.

Examination of the UPDRS bradykinesia subscale: equivalence, reliability and validity.

Buck PO, Wilson RE, Seeberger LC, Conner JB, Castelli-Haley J.

J Parkinsons Dis. 2011;1(3):253-8. doi: 10.3233/JPD-2011-11035.

PMID:
23939305
5.

Movement disorders associated with aripiprazole use: a case series.

Hall DA, Agarwal P, Griffith A, Segro V, Seeberger LC.

Int J Neurosci. 2009;119(12):2274-9. doi: 10.3109/00207450903225553.

PMID:
19916856
6.

Levodopa/carbidopa/entacapone in Parkinson's disease.

Seeberger LC, Hauser RA.

Expert Rev Neurother. 2009 Jul;9(7):929-40. doi: 10.1586/ern.09.64.

PMID:
19589043
7.

Optimizing bioavailability in the treatment of Parkinson's disease.

Seeberger LC, Hauser RA.

Neuropharmacology. 2007 Dec;53(7):791-800. Epub 2007 Sep 6. Review.

PMID:
17936857
8.

MS vs. HD: can white matter and subcortical gray matter pathology be distinguished neuropsychologically?

Lafosse JM, Corboy JR, Leehey MA, Seeberger LC, Filley CM.

J Clin Exp Neuropsychol. 2007 Feb;29(2):142-54.

PMID:
17365249
9.

Efficacy and safety of botulinum type A toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study.

Truong D, Duane DD, Jankovic J, Singer C, Seeberger LC, Comella CL, Lew MF, Rodnitzky RL, Danisi FO, Sutton JP, Charles PD, Hauser RA, Sheean GL.

Mov Disord. 2005 Jul;20(7):783-91.

PMID:
15736159
10.

By carrot or by stick: cognitive reinforcement learning in parkinsonism.

Frank MJ, Seeberger LC, O'reilly RC.

Science. 2004 Dec 10;306(5703):1940-3. Epub 2004 Nov 4.

11.

A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia.

Hauser RA, Friedlander J, Zesiewicz TA, Adler CH, Seeberger LC, O'Brien CF, Molho ES, Factor SA.

Clin Neuropharmacol. 2000 Mar-Apr;23(2):75-81.

PMID:
10803796
12.

Clozapine use in Parkinson's disease: a retrospective analysis of a large multicentered clinical experience.

Trosch RM, Friedman JH, Lannon MC, Pahwa R, Smith D, Seeberger LC, O'Brien CF, LeWitt PA, Koller WC.

Mov Disord. 1998 May;13(3):377-82.

PMID:
9613725
13.

Spasticity after stroke. Epidemiology and optimal treatment.

O'Brien CF, Seeberger LC, Smith DB.

Drugs Aging. 1996 Nov;9(5):332-40. Review.

PMID:
8922560

Supplemental Content

Loading ...
Support Center